ATG-019 (also known as KPT-9274) is a first-in-class, oral modulator of p21-activated kinase 4 (PAK4) and nicotinamide phosphoribosyltransferase (NAMPT). We are in partnership with Karyopharm Therapeutics for clinical development, manufacturing and commercialization of ATG-019 in mainland China, Taiwan, Hong Kong, Macau, South Korea and ASEAN countries.
PAK4 is a protein that regulates numerous fundamental cellular processes, including intracellular transport, cellular division, cell shape and motility, cell survival, immune defense and the development of cancer. PAK4 interacts with many key signaling molecules involved in cancer such as beta-catenin, CDC42, Raf-1, BAD and myosin light chain. NAMPT is a pleiotropic protein with intra- and extra-cellular functions as an enzyme, cytokine, growth factor, and hormone that can be found in complex with PAK4 in the cell.
ATG-019 has demonstrated potent anti-tumor activity in pre-clinical studies and in patient dogs with cancer (i.e., diffuse large B-cell lymphoma). The compound is currently in Phase 1 study for evaluation of its safety, tolerability, and efficacy in patients with advanced solid malignancies or non-Hodgkin’s lymphoma.